Neonatal 6-hydroxydopamine administration to mice is fatal

Developmental Neuroscience

Volumn 24, Issue 6, 2002, Pages 531-538

  Brot, Michelle D ^a   Szczypka, Mark S ^b   Reavell, Randy ^a   Marck, Brett T ^a   Matsumoto, Alvin M ^a,c   Palmiter, Richard D ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

6 Hydroxydopamine; Compensation, dopamine depletion; Dopamine; Neonatal mice, 6 hydroxydopamine administration; Serotonin

Indexed keywords

CATECHOLAMINE; DOPAMINE; OXIDOPAMINE;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; ENERGY; ENVIRONMENTAL TEMPERATURE; FEMALE; GENOTYPE; MALE; MOTOR COORDINATION; MOUSE; NEUROTOXICITY; NEWBORN; NEWBORN PERIOD; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

ADRENERGIC AGENTS; ANIMALS; ANIMALS, NEWBORN; AROMATIC-L-AMINO-ACID DECARBOXYLASES; BEHAVIOR, ANIMAL; BODY WEIGHT; BRAIN; BRAIN CHEMISTRY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; FEMALE; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENTRICULAR; MALE; MICE; MICE, TRANSGENIC; OXIDOPAMINE; TEMPERATURE; TYROSINE 3-MONOOXYGENASE;

EID: 0344406158     PISSN: 03785866     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069364     Document Type: Article

References (38)

1. Berger TW, Kaul S, Stricker EM, Zigmond MJ (1985): Hyperinnervation of the striatum by dorsal raphe afferents after dopamine-depleting brain lesions in neonatal rats. Brain Res 336:354-358.
2. Björklund A, Wiklund L, Descarries L (1981): Regeneration and plasticity of central serotoninergic neurons: A review. J Physiol (Paris) 77: 247-255.
3. Breese GR, Baumeister AA, McCown TJ, Emerick SG, Frye GD, Crotty K, Mueller RA (1984): Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: Relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. J Pharmacol Exp Ther 231:343-354.
4. Breese GR, Napier TC, Mueller RA (1985): Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: Functional supersensitivity of D1 receptors in neonatally lesioned rats. J Pharmacol Exp Ther 234:447-455.
5. Bruno JP, Jackson D, Zigmond MJ, Stricker EM (1987): Effect of dopamine-depleting brain lesions in rat pups: Role of striatal serotonergic neurons in behavior. Behav Neurosci 101:806-811.
6. Bruno JP, Sandström MI, Arnold HM, Nelson CL (1998): Age-dependent neurobehavioral plasticity following forebrain dopamine depletions. Dev Neurosci 20:164-179.
7. Bruno JP, Snyder AM, Stricker EM (1984): Effect of dopamine-depleting brain lesions on suckling and weaning in rats. Behav Neurosci 98: 156-161.
8. Bruno JP, Zigmond MJ, Stricker EM (1986): Rats given dopamine-depleting brain lesions as neonates do not respond to acute homeostatic imbalances as adults. Behav Neurosci 100:125-128.
9. Fink D, Horn PT, Mirkin BL (1992): Differential effects of 6-hydroxydopamine-induced ablation of peripheral and central adrenergic axons on C-1300 murine neuroblastoma tumor growth and catecholamine concentration in the A/J mouse. J Pharmacol Exp Ther 262:1070-1075.
10. Frohna PA, Neal-Beliveau BS, Joyce JN (1997): Delayed plasticity of the mesolimbic dopamine system following neonatal 6-OHDA lesions. Synapse 25:293-305.
11. Gerfen CR (2000): Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci 23(10 Suppl):64-70.
12. Imamoto K, Nagai T, Kimura H, Maeda T (1980): Effect of neonatal administration of 6-OHDA on the brain development. I. Alteration in the striatum. Arch Histol Jpn 43:347-364.
13. Jaber M, Robinson SW, Missale C, Caron MG (1996): Dopamine receptors and brain function. Neuropharmacology 35:1509-1519.
14. Joyce JN, Frohna PA, Neal-Beliveau BS (1996): Functional and molecular differentiation of the dopamine system induced by neonatal denervation. Neurosci Biobehav Rev 20:453-486.
15. Kim DS, Szczypka MS, Palmiter RD (2000): Dopamine-deficient mice are hypersensitive to dopamine receptor agonists. J Neurosci 20:4405-4413.
16. Lovell KL (1981): Changes in brain norepinephrine content in mice following neonatal 6-hydroxydopamine. Brain Res Bull 7:41-44.
17. Lytle LD, Shoemaker WJ, Cottman K, Wurtman RJ (1972): Long-term effects of postnatal 6-hydroxydopamine treatment on tissue catecholamine levels. J Pharmacol Exp Ther 183: 56-64.
18. Marshall JF, Richardson JS, Teitelbaum P (1974): Nigrostriatal bundle damage and the lateral hypothalamic syndrome. J Comp Physiol Psychol 87:808-830.
19. Matsuura K, Kabuto H, Makino H, Ogawa N (1997): Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J Neurosci Methods 73:45-48.
20. Potter BM, Bruno JP (1989): Food intake of rats depleted of dopamine as neonates is impaired by inhibition of catecholamine biosynthesis. Neurosci Lett 107:295-300.
21. Reader TA, Dewar KM (1999): Effects of denervation and hyperinnervation on dopamine and serotonin systems in the rat neostriatum: Implications for human Parkinson's disease. Neurochem Int 34:1-21.
22. Rogers DC, Dunnett SB (1989): Hypersensitivity to α-methyl-p-tyrosine suggests that behavioural recovery of rats receiving neonatal 6-OHDA lesions is mediated by residual catecholamine neurones. Neurosci Lett 102:108-113.
23. Segler-Stahl K, Rahmann H, Rosner H (1982): Effects of neonatal 6-hydroxydopamine treatment on cortical development in mice and rats as monitored by developmental changes of gangliosides. Dev Neurosci 5:554-556.
24. Shimizu T, Izumi K, Fujita S, Koja T, Sorimachi M, Ohba N, Fukuda T (1987): Capsaicin-induced corneal lesions in mice and the effects of chemical sympathectomy. J Pharmacol Exp Ther 243:690-695.
25. Snyder AM, Zigmond MJ, Lund RD (1986): Sprouting of serotoninergic afferents into striatum after dopamine-depleting lesions in infant rats: A retrograde transport and immunocytochemical study. J Comp Neurol 245:274-281.
26. Staal RG, Hogan KA, Liang CL, German DC, Sonsalla PK (2000): Monoamine transporter (VMAT2): Rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium. J Pharmacol Exp Ther 293:329-335.
27. Staal RGW, Sonsalla PK (2000): Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata. J Pharmacol Exp Ther 293:336-342.
28. Stachowiak MK, Bruno JP, Snyder AM, Stricker EM, Zigmond MJ (1984): Apparent sprouting of striatal serotonergic terminals after dopamine-depleting brain lesions in neonatal rats. Brain Res 291:164-167.
29. Szczypka MS, Mandel RJ, Donahue BA, Snyder RO, Leff SE, Palmiter RD (1999a): Viral gene delivery selectively restores feeding and prevents lethality of dopamine-deficient mice. Neuron 22:167-178.
30. Szczypka MS, Rainey MA, Kim DS, Alaynick WA, Marck BT, Matsumoto AM, Palmiter RD (1999b): Feeding behavior in dopamine-deficient mice. Proc Natl Acad Sci USA 96:12138-12143.
31. Takeuchi Y, Sawada T, Jenner P (1991): Plasticity in dopamine-deficient neonates. Brain Dysfunct 4:93-103.
32. Thomas SA, Matsumoto AM, Palmiter RD (1995): Noradrenaline is essential for mouse fetal development. Nature 374:643-646.
33. Ungerstedt U (1971): Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 367:95-122.
34. Yamazoe I, Takeuchi Y, Matsushita H, Kawano H, Sawada T (2001): Serotonergic heterotypic sprouting in the unilaterally dopamine-depleted mouse neostriatum. Dev Neurosci 23: 78-83.
35. Zhou QY, Palmiter RD (1995): Dopamine-deficient mice are severely hypoactive, adipsic and aphagic. Cell 83:1197-1209.
36. Zhou QY, Quaife CJ, Palmiter RD (1995): Targeted disruption of the TH gene reveals that catcholamines are required for mouse fetal development. Nature 374:640-643.
37. Zigmond MJ, Stricker EM (1973): Recovery of feeding and drinking by rats after intraventricular 6-hydroxydopamine or lateral hypothalamic lesions. Science 182:717-720.
38. Zigmond MJ, Stricker EM (1985): Adaptive properties of monoaminergic neurons and their functional implications; in Lajtha A (ed): Handbook of Neurochemistry. New York, Plenum Press, vol. 9, pp 87-102.